References
- Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlatin of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177–82.
- BaseIga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol, 1996; 14: 737–44.
- Vogel Cl, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719–726.
- Slamon DJ, Leyland Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001; 44: 783–792.
- Robert N, Leyland-Jones B, Asmar L et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER2/neu positive advanced breast cancer. SABCS 2002, Abst 35.
- Perez EA, Rowland KM, Sumam VJ et al. Efficacy and tolerability of two schedules of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC): a North Central Treatment Group (NCCTG) randomized phase II trial. SABCS 2003; abst 216.
- Konecny G, Pegram MD, Berty M et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER2/neu overexpression. Breast Cancer Res Treat 1999; 57:114.
- Extra JM, Cognetti F, Chan S et al. Randomized phase II trial (M77001) of trastuzumab plus docetaxel versus docetax-el alone, as first-line therapy in patients with HER2-positive metastatic breast cancer. Eur J Cancer 2003; abs. 672.
- Malik MA, Totpal K, Baiter I et al. Dose response stud-ies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models. Proc AACR 2003; 44:773.
- Agus DB, Gordon M, Taylor C et al. Clinical activity in a phase I trial of HER2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies (AST). Proc Am Soc Clin Oncol 2003; 22:192.